This page shows the latest Orencia news and features for those working in and with pharma, biotech and healthcare.
Overall, BMS reported fourth-quarter revenues up 22% to $5.2bn, with a solid showing from novel oral anticoagulant Eliquis (apixaban), which leaped 57% to $346m and rheumatoid arthritis therapy Orencia
Away from cancer, rheumatoid arthritis treatment Orencia (abatacept) continued its buoyant run with an 18% increase to $572m, while novel oral anticoagulant Eliquis (apixaban) brought in $884m, a rise of 90%.
It also has a biosimilar collaboration with generics giant Mylan covering six biologics, headed by M834, a biosimilar version of Bristol-Myers Squibb's rheumatoid arthritis drug Orencia (abatacept).
Mylan buys into six biosimilars, including Orencia candidate. Deal with Momenta bolsters biosimilars pipeline for new products. ... The agreement gives Mylan the rights to six biosimilars in Momenta's pipeline, including a version of Bristol-Myers
NICE backs four treatments for juvenile idiopathic arthritis. Includes BMS' Orencia and AbbVie's Humira. ... The institute backed Bristol-Myers Squibb's Orencia (abatacept), AbbVie's Humira (adalimumab), Pfizer's Enbrel (etanercept) and Roche's RoActemra
Orencia (abatacept) and MSD/J&J's Remicade (infliximab).
More from news
Approximately 10 fully matching, plus 33 partially matching documents found.
255. Mylan/ Momenta. Co-development, co-commercialisation . Exclusive global collaboration with Momenta for 6 biosimilars including a biosimilar version of Orencia (abatacept).
Orencia and Actemra for rheumatoid arthritis.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Dr Daniels has been with BMS since 2000 as VP of the immunology, pulmonary, and dermatology therapeutic area where he worked on such compounds as rheumatoid arthritis drug Orencia (abatacept).
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
market leaders Enbrel (etanercept) and Humira (adalimumab) will continue to lose market share to newer biologics such as RoActemra (tocilizumab), Orencia (abatacept) and Simponi (golimumab) and may experience strong competition from
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
StratX creates experiential learning programs instilled with emotion and competitive spirit, leading to lasting on-the-job change. Our memorable approach develops...